Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$31.64
▼ $0.48 (-1.5%)
Market data updated: 09/19 03:52 AM
Fundamentals updated: 09/19/2026
News analyzed: 09/19/2026
Market Cap
Not available
Day Range
$31.49 - $32.33
52-Week Range
$31.49 - $50.88
Beta
—
Next Earnings
—
Support
$31.49
Resistance
$42.19
MDLN is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-22.8% (1Y)
Strengths: 1/13 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🔴 Bearish
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Operating margin stability
Operating margin is stable or improving over time
Quality
Biggest negative driver
Daily volatility (ATR)
ATR: 4.5% of price
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 0 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 0
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
43
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
44
Quality
58
Value
50
Momentum
18
Risk
42
Sentiment
68
Fundamental
50
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Medline Inc. has primarily centered on financial and operational challenges, including cost pressures delaying profit recovery, as highlighted by Artisan Partners’ decision to sell the stock in Q2 2026. Additionally, the company faced regulatory scrutiny over a recall-related correction involving B. Braun bupivacaine components in its convenience kits, linked to 35 serious injuries. Analysts like BTIG and Tigress Financial maintained a positive outlook with a $55 price target, while Medline’s leadership participated in the Morgan Stanley Global Healthcare Conference to address investor concerns.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Medline Inc.. News trend score: 68. Reason: 8 of the last 20 articles are positive, versus 5 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
25
🎯 Conviction (vs. Emotion)
52
Psychology
91
Fundamentals
50
Technical
18
Valuation
50
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price (3M)
-12%
Market Narrative
40
Fundamental Reality
52
Narrative Gap
-12
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market behavior suggests **herding** dominates, as MDLN’s underperformance relative to peers (-4.0% vs. -1.9%) aligns with passive trend-following. FOMO’s presence (29) hints at opportunistic buying, but momentum and volume remain modest, avoiding extreme euphoria. Anchoring’s slight signal (11.2% from support) may reflect hesitation to deviate from recent trends. The narrow narrative gap (1 point) implies no major disconnect between sentiment and fundamentals. The key question: *Will herding persist if MDLN diverges further from peers?*
Updated: 09/08/2026, 03:51 PM
What could change this?
👥 What the crowd believes
"FDA alerts providers as Medline corrects convenience kits with recalled BD applicators due to sterility and contamination risks."
"Tigress Financial Adjusts Medline Price Target to $55 From $62, Maintains Buy Rating."
"Cost pressures delayed the Company’s profit recovery."
📈 12D Investor Psychology
Signal classification confidence: Medium (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Samuel Armstrong Nelson — 96/100
🔴 Weakest match
Morgan Housel — 0/100
🗣️ Why do they disagree?
Based on the documented principles, the model estimates that sentiment‑oriented investors such as Mackay (score 86) and Nelson (score 77) view the environment favorably, noting no crowd mania and an oversold cycle, while growth‑focused thinkers like Fisher (80) and Lynch (75) are constrained by insufficient fundamental data. Value‑oriented frameworks from Graham and Bagehot sit near the midpoint (scores around 50) because they lack the balance‑sheet detail needed for a definitive valuation. Marks’s two lenses diverge, with his cycle view (57) placing the stock in the middle of the cycle but his overall assessment (46) flagging potentially high expectations. More contrarian or risk‑averse approaches – Schwager (52), Smith (45), Veblen (42) and the efficient‑market view (31) – express mixed or weak cases, and the most trend‑following or volatility‑sensitive models (Livermore 19, Housel 0) turn sharply negative.
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 96
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 86
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟢 80
Not enough fundamentals data for a real Fisher read
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 20%
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟢 75
Not enough growth data for a real Lynch read
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 15%
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 68
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟢 66
A real, disciplined setup with favorable reward/risk
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 50
Not enough balance-sheet/valuation data for a real Graham read
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Walter Bagehot
Lombard Street (1873)
🟡 50
Not enough balance-sheet data for a real Bagehot read
Key question
Does this company have enough liquidity to survive real stress?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 50
Not enough valuation data for a real Enterprising-Graham read
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 46
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 45
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 42
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🔴 26
Weak case — Malkiel/Bogle would say a low-cost index is the simpler bet
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🔴 26
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 22
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 0
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Based on the last 189 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (0 bullish · 9 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
—
Net Margin
—
EBITDA Margin
—
ROE
—
ROA
—
ROIC
—
EPS
—
Cash
—
Total Debt
—
Current Ratio
—
Debt/Equity
—
Not enough data to compute signals.
אין נתונים היסטוריים זמינים.
How is Fair Value calculated? →
Not enough cash-flow data to calculate a DCF model for this stock.
Book Value per Share
—
Tangible Book Value per Share (Tangible NAV)
—
Not enough data to compute signals.
Sentiment based on basic keywords (not AI) — 8 positive, 7 neutral, 5 negative out of the last 20 articles.
Yahoo · 16.9.2026
SeekingAlpha · 16.9.2026
SeekingAlpha · 15.9.2026
Yahoo · 10.9.2026
Insider Monkey · 10.9.2026
Yahoo · 4.9.2026
Insider Monkey · 4.9.2026
Yahoo · 3.9.2026
GlobeNewswire · 3.9.2026
Benzinga · 27.8.2026
Benzinga · 20.8.2026
SeekingAlpha · 19.8.2026
MT Newswires · 14.8.2026
SeekingAlpha · 14.8.2026
Benzinga · 13.8.2026
Motley Fool · 12.8.2026
Benzinga · 12.8.2026
Benzinga · 11.8.2026
Benzinga · 10.8.2026
MT Newswires · 6.8.2026
Medline Inc. (MDLN) currently has a StockIQ AI score of 43/100, rated "Weak". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
MDLN currently scores 43/100 (Weak) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
MDLN's technical score is 18/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Operating margin is stable or improving over time.
Based on the real signals StockIQ computed: ATR: 4.5% of price; Net income growth: -0.9%; Price is below the 50-day average.
StockIQ has no recorded dividend payment history for MDLN.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 12 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Boyle James M | Grant/Award from Employer | 19.8.2026 | 764,252 | +764,252 | — |
| Miller Stephen L | Grant/Award from Employer | 19.8.2026 | 87,667 | +87,667 | — |
| GIC Private Ltd | Open Market Sale | 14.8.2026 | 100,000 | -100,000 | $35.80 |
| GIC Private Ltd | Open Market Sale | 13.8.2026 | 1,500,000 | -1,500,000 | $35.80 |
| GIC Private Ltd | Open Market Sale | 7.8.2026 | 590,284 | -590,284 | $35.58 |
| GIC Private Ltd | Open Market Sale | 7.8.2026 | 24,402,482 | -590,284 | $35.58 |
| GIC Private Ltd | Open Market Sale | 6.8.2026 | 271,994 | -271,994 | $35.33 |
| Mozart Holdco, Inc. | Conversion of Derivative Security | 6.8.2026 | 500,000 | -500,000 | — |
| Mozart Holdco, Inc. | Conversion of Derivative Security | 6.8.2026 | 500,000 | +500,000 | — |
| Mozart Holdco, Inc. | Other Transaction | 6.8.2026 | 500,000 | -500,000 | — |
| GIC Private Ltd | Open Market Sale | 6.8.2026 | 24,992,766 | -271,994 | $35.33 |
| Mozart Holdco, Inc. | Conversion of Derivative Security | 6.8.2026 | 787,648 | +500,000 | — |
| Mozart Holdco, Inc. | Conversion of Derivative Security | 6.8.2026 | 233,520,656 | -500,000 | — |
| Mozart Holdco, Inc. | Other Transaction | 6.8.2026 | 233,520,656 | -500,000 | — |
| GIC Private Ltd | Open Market Sale | 5.8.2026 | 265,711 | -265,711 | $36.48 |
| GIC Private Ltd | Open Market Sale | 5.8.2026 | 1,710,907 | -1,710,907 | $35.46 |
| GIC Private Ltd | Open Market Sale | 5.8.2026 | 25,530,471 | -1,710,907 | $35.46 |
| GIC Private Ltd | Open Market Sale | 5.8.2026 | 25,264,760 | -265,711 | $36.48 |
| Golwas Douglas P | Exercise of Derivative Securities | 16.6.2026 | 100,000 | -100,000 | — |
| Golwas Douglas P | Disposition to the Company | 16.6.2026 | 100,000 | -100,000 | — |
| Golwas Douglas P | Open Market Sale | 16.6.2026 | 61,966 | -61,966 | $36.60 |
| Golwas Douglas P | Exercise of Derivative Securities | 16.6.2026 | 100,000 | +100,000 | — |
| Golwas Douglas P | Open Market Sale | 16.6.2026 | 38,034 | -38,034 | $37.05 |
| Boyle James M | Tax Withholding in Shares | 15.6.2026 | 2,370 | -2,370 | $36.61 |
| Liberman Alexander M. | Tax Withholding in Shares | 15.6.2026 | 872 | -872 | $36.61 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
39,481,289 shares short as of 2026-08-31 · vs. 34,562,171 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
57.6% of trading volume this week was short selling, vs. 63.8% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology